Affymetrix Announces Expansion of QuantiGene® ViewRNA License for in vitro Diagnostics & Becomes Exclusive Licensee for Chro...
August 01 2012 - 7:30AM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) today announced the expansion of
its license agreement with Siemens Healthcare Diagnostics for the
company’s branched DNA (bDNA) technology whereby Affymetrix is the
exclusive licensee for in situ products, including in vitro
diagnostics. This expanded license grants Affymetrix rights to
develop and sell in situ QuantiGene® ViewRNA products, currently
for research use only, in the in vitro diagnostic market.
Additionally, this license includes exclusive rights to alkaline
phosphatase conjugated oligonucleotides and their use in bDNA
methods for in situ detection utilizing Fast Red substrates. In
light of this expanded license, along with existing technology and
other recently announced collaborations, such as the research
collaboration with Massachusetts General Hospital, the automation
collaboration with Leica Microsystems, and the worldwide
distribution of ScreenCell’s circulating tumor cell technology,
Affymetrix plans to commercialize a platform of total solutions
involving an assay menu of chromogenic-based applications of the
bDNA technology which provide highly sensitive, multiplex analyses
in both brightfield (CISH) and fluorescence (FISH) microscopy and
options for automation.
“This agreement provides Affymetrix with an important
opportunity to enable clinical researchers and pathologists using
advanced histo-staining techniques to combine the anatomical
analysis with a molecular-level understanding. Advanced in situ RNA
hybridization methods applied to formalin fixed paraffin-embedded
[FFPE], fine-needle aspirates [FNAs], and other clinical samples
have the potential of becoming powerful new tools to translate
biomarker signatures to diagnostics that enable clinicians to
personalize patient care,” stated George Bers, Vice President and
General Manager of Gene Expression Business Unit - Panomics at
Affymetrix. “These predictable, two-plex, highly-sensitive and
specific chromogenic assays help move the analysis to the next
level by literally analyzing any expressed gene at the single
transcript per single cell level.”
Affymetrix currently offers a broad range of bDNA technology
based assays, including QuantiGene®, QuantiGene® Plex, and
QuantiGene® ViewRNA, for single and multiplex in situ tissue, in
situ cellular, and direct-from-sample, quantitative RNA and DNA
copy number variation analyses. These assays are used for biomarker
discovery and validation applications in drug discovery, early
phase clinical trials, pathology, translational sciences, and
cancer research as well as other disease-related research.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip,
QuantiGene and all other trademarks are the property of Affymetrix,
Inc. All other trademarks are the property of their respective
owners.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies, as well as
leading academic, government, and nonprofit research institutes.
More than 26,000 peer-reviewed papers have been published citing
the technologies. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Santa Clara, San Diego,
Cleveland, Ohio, Singapore, and Austria. The company has about
1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024